+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Intranasal Drug Delivery - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 459 Pages
  • October 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 516888

Global Intranasal Drug Delivery Market to Reach $75.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Intranasal Drug Delivery estimated at US$49.5 Billion in the year 2020, is projected to reach a revised size of US$75.4 Billion by 2027, growing at a CAGR of 6.2% over the period 2020-2027. Liquid Delivery Devices, one of the segments analyzed in the report, is projected to record a 5.8% CAGR and reach US$31.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Powder Delivery Devices segment is readjusted to a revised 7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $20.8 Billion, While China is Forecast to Grow at 8.4% CAGR

The Intranasal Drug Delivery market in the U.S. is estimated at US$20.8 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$6.1 Billion by the year 2027 trailing a CAGR of 8.4% over the period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.6 Billion by the year 2027.

Pressurized Metered Dose Inhalers Segment to Record 6.4% CAGR

In the global Pressurized Metered Dose Inhalers segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$7 Billion in the year 2020 will reach a projected size of US$10.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 7.5% CAGR through the analysis period.

Select Competitors (Total 77 Featured)

  • AptarGroup, Inc.
  • AstraZeneca Plc.
  • Becton Dickinson and Company
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • Nemera
  • Novartis AG
  • OptiNose US Inc.
  • Pfizer, Inc.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to a digital archives and Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Intranasal Drug Delivery

What is the estimated value of the Global Market for Intranasal Drug Delivery?

The Global Market for Intranasal Drug Delivery was estimated to be valued at $49.5 Billion in 2020.

What is the growth rate of the Global Market for Intranasal Drug Delivery?

The growth rate of the Global Market for Intranasal Drug Delivery is 6.2%, with an estimated value of $75.4 Billion by 2027.

What is the forecasted size of the Global Market for Intranasal Drug Delivery?

The Global Market for Intranasal Drug Delivery is estimated to be worth $75.4 Billion by 2027.

Who are the key companies in the Global Market for Intranasal Drug Delivery?

Key companies in the Global Market for Intranasal Drug Delivery include AptarGroup, Inc., AstraZeneca Plc., Becton Dickinson and Company, GlaxoSmithKline Plc., Johnson & Johnson Inc., Merck & Co., Inc., Nemera, Novartis AG and Pfizer, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Impact of Covid-19 and a Looming Global Recession
  • 2020: A Year of Disruption & Transformation
  • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021?
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • Promising Intranasal Vaccines to Nip COVID-19 Virus at Point of Entry
  • Rapid Progress despite Roadblocks
  • Nasal Sprays for Protection against COVID-19 Infection
  • Influencer Market Insights
  • World Market Trajectories
  • Intranasal Drug Delivery - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Intranasal Drug Delivery: A Prelude
  • Leading Indications and APIs Amenable to Nasal Drug Delivery
  • Regional Market Analysis
  • Why Nasal Application is Garnering Notable Attention for Drug Delivery
  • Limitations of Intranasal Drug Delivery
  • Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
  • Drug Delivery Pathways Related to the Nasal Cavity
  • Systemic delivery and Local Delivery Routes
  • Differences between Systemic Delivery and Local Effects
  • Challenges Involved In Formulating Nasal Drugs
  • Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
  • Nose-to-Brain Drug Delivery: An Evolving Area of Interest
  • Factors Inhibiting Nose-to-Brain Transportation of Drugs
  • Bioavailability: An Important Facet of Intranasal Drug Delivery
  • Traditional Vs. Advanced Intranasal Drug Formulation Types
  • Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application
  • Select FDA-Approved Nasal Products Compound (Trade Name) Indication Dosage Form Year
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rise in Prevalence of COPD Drives Opportunities
  • Global Prevalence of COPD: Percentage of Men and Women Affected by Age Group
  • Pharmaceutical and Medical Device Companies Vie to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients
  • Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries
  • The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
  • The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
  • Intranasal Corticosteroids : A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease
  • Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage
  • Manufacturers Focus on Improved Nasal Delivery Platforms
  • Controlled Release Technology is the Buzz Word
  • Research on Nanocarrier-Based Intranasal Drug Delivery Systems Picks Up Pace
  • Potential Role in Treatment and Management of Coronavirus Infection
  • Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight
  • Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
  • Top Nasal Inhalers, Sprays, and Drops Brands in the US (2019): Percentage Share Breakdown of Dollar Sales
  • Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications
  • Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery
  • Intranasal Therapeutics Delivery: A High Potential Method for Treating CNS Diseases
  • Researchers Develop Nasal Spray Treatment for Parkinson's Disease
  • Future Opportunities in CNS Space
  • Intranasal Delivery of Stem Cells: A Primary Strategy for Treatment of CNS Disorders
  • Intranasal Delivery of Stem Cells: Limitations
  • Diagnosed Prevalence Cases of Parkinson's Disease Across Select Countries
  • Intranasal Delivery of Peptide-Based Pharmaceuticals
  • Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace
  • Select List of Nasal Biologics Available in the Market
  • Benefits of Bi-Directional Nasal Drug Delivery
  • Rise in Interest in Preservative-free Nasal Spray Formulations
  • Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Appendix: List of Select Intranasal Drugs in Phase III Clinical Trials
  • List of Select Intranasal Drugs for Pain Management in Phase III Clinical Trials
  • Select Intranasal Drugs for Cancer in Phase III Clinical Trials
  • Select Intranasal Drugs for Diabetes in Phase III Clinical Trials
  • Select Intranasal Drugs for Nasal Polyps in Phase III Clinical Trials
  • Select Intranasal Drugs for Depression in Phase III Clinical Trials
  • Select Intranasal Drugs for Chronic Sinusitis in Phase III Clinical Trials
  • Select Intranasal Drugs for Migraine in Phase III Clinical Trials
  • Intranasal Drugs for Allergic Rhinitis in Phase III Clinical Trials
  • Select Intranasal Drugs for Diabetes Mellitus in Phase III Clinical Trials
  • Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials
  • Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Liquid Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Liquid Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 3: World 11-Year Perspective for Liquid Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 4: World Recent Past, Current & Future Analysis for Powder Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Powder Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 6: World 11-Year Perspective for Powder Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 7: World Recent Past, Current & Future Analysis for Pressurized Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Pressurized Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 9: World 11-Year Perspective for Pressurized Metered Dose Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 10: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 12: World 11-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 13: World Recent Past, Current & Future Analysis for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 15: World 11-Year Perspective for Respiratory Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 16: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 18: World 11-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 19: World Recent Past, Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 21: World 11-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 24: World 11-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2021 & 2027
  • Table 25: World Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 26: World Historic Review for Intranasal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2019 and % CAGR
  • Table 27: World 11-Year Perspective for Intranasal Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2016, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
CANADA
JAPAN
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
CHINA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
EUROPE
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
FRANCE
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
GERMANY
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
ITALY
UNITED KINGDOM
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
AUSTRALIA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
INDIA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
IV. COMPETITION
  • Total Companies Profiled: 77

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AptarGroup, Inc.
  • AstraZeneca Plc.
  • Becton Dickinson and Company
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • Nemera
  • Novartis AG
  • OptiNose US Inc.
  • Pfizer, Inc.